[1]
“GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE ”, GSR, vol. 2, no. 1, pp. 418–422, Mar. 2025, Accessed: Nov. 16, 2026. [Online]. Available: https://global-science-review.com/ojs/index.php/gsr/article/view/238